How To Manage Formulation Of High Concentration Biologics

We see a trend towards increasingly concentrated drug formulations due, for example, to the decreasing popularity of intravenous administration. This trend presents manufacturing challenges. In this presentation, Parviz Shamlou, Vice President of the Jefferson Institute for Bio-Processing discusses the challenges associated with high concentration and high viscosity monoclonal antibody formulations, how biopharma manages these challenges today and how the Jefferson Institute addresses these issues.

Kendal Studd, Scientific Applications Specialist at Advanced Instruments will close the session by discussing the challenges for analytical devices in testing these formulations and how advances in osmolality testing in particular are applied to help minimize the risks.